...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

The World’s First Smart Insulin Pens with Automatic Wireless Data Transfer (868 MHz or Bluetooth®)

| Print |
Thursday, 04 August 2016 13:00 (UTC + 2)

Emperra logo new

Fully automated data transfer improves diabetes management

Potsdam, Germany, August 4, 2016 / B3C newswire / -- Emperra GmbH based in Germany is launching the world’s first Bluetooth® insulin pen on the market and therefore expanding its ESYSTA® product system’s function. The new ESYSTA® BT pen is equipped with a Bluetooth® interface and transfers the injected insulin doses directly to the patient’s digital blood glucose diary. The smart insulin pens automatically connected via the 868 MHz interface (similar to the ISM band) are already being successfully used in medicine in combination with a wireless transmission blood glucose meter as an integrated diabetes management system, ESYSTA®. Both the hardware components and software solutions (ESYSTA® portal, ESYSTA® app) have been certified as CE-compliant medical products. Patients and doctors can achieve a new quality of medical care for Type 1 and Type 2 diabetics using the patented ESYSTA® solution. On the basis of the available scientific data and reimbursement by statutory health insurance companies on the complex German healthcare market, Emperra is striving to use this smart insulin pen based ESYSTA® telemonitoring solution with an FDA filing process for the US market. FDA clearance is expected in 2016.

Esysta-BT pen

Caption: The ESYSTA® BT pen allows for the direct transfer of insulin data to automatically keep a diary

“The smart insulin pen and corresponding software appeal to patients and doctors who prefer state-of-the-art technical solutions and who have recognised that the digitalisation of diabetes management is a simple and reliable solution,” summarises Dr. Christian Krey, CEO of Emperra GmbH.

With the help of innovative sophisticated software solutions compliant with medical products and the highest integrated data security standards ISO/IEC 27001, several teams of doctors can even solve complex issues with patients whose levels are hard to adjust telemedically for the first time worldwide using unadulterated insulin data from insulin pens.

The mobile CE-compliant ESYSTA® app for iOS® and Android® plays the treatment recommendations back, among other things using innovative traffic light algorithms. ESYSTA® convinced most patients, their doctors and care-givers within the first few months during a medical and health economic field trial by German health insurance companies. Besides being listed in the reimbursement catalogue of all statutory health insurance companies, digital diabetic services are being contractually agreed as an important business area for Emperra for the first time in Germany.

Emperra is therefore the only company that can reach all age groups of people with diabetes mellitus using a holistic innovative approach of digital solutions with smart insulin pens. The largest population of older Type 2 diabetics treated with insulin is being digitally reached for the first time as a result.

Esysta system

Caption: ESYSTA®: Web-based telemonitoring system consisting of a base unit, insulin pen, blood glucose meter, app and online portal.

“We are proud that we can use all U-100 insulins in 3 ml cartridges with the development of specially customised adapters. As a result every insulin-dependent patient can be equipped with ESYSTA®, regardless of whether the insulin comes from Lilly®, Sanofi® or Novo Nordisk®. Even the accidental mixing up of basal and bolus ESYSTA® pens and priming (deaeration) can be identified on the ESYSTA® portal. In combination with real insulin application data, I believe as a doctor that this constitutes an evolutionary leap for the digital age of diabetes management,” says Dr. Janko Schildt, Founder and Managing Director responsible for medicine and technology.

Effective reduction in HbA1c thanks to digitalised diabetes management
The seamless documentation of insulin units and blood glucose levels is an important element of diabetes treatment. Many people with diabetes measure their blood glucose several times a day and inject insulin. The data has to be continuously documented and analysed for the best metabolic control. An annoying undertaking for the doctor and patient. “Often the patient’s entries are difficult to read or simply forgotten, analysing the data is laborious and time-consuming,” Prof. Dr. Dr. Klaus Kusterer, a diabetologist from Mannheim, describes many doctors’ everyday practice. “Digital data recording can make a huge contribution to improving diabetes management.” Insulin doses and blood glucose levels are automatically recorded using the ESYSTA® system. “The data is complete and unadulterated and the patient no longer has to remember to document their data at all,” says Professor Kusterer.

In a study together with a health insurance company, the ESYSTA® system was tested by several hundreds of insulin-dependent diabetics in everyday practice. Conclusion: HbA1c could be reduced by almost 1% on average over a period of twelve months. In patients with significantly higher HbA1c levels at the start, a reduction of up to 2% could even be achieved without the hypoglycaemic rate (low blood sugar emergencies) rising, according to the health insurance company’s information. Diabetes experts rate these results as extremely positive, especially as even the insulin consumption, an important cost factor, tended to also be reduced in most patients.

Outlook
At the start of 2017 there will be another integrated data transfer solution, the world’s smallest GSM-compatible blood glucose meter, which automatically digitally transfers the 868 MHz insulin pen with blood glucose levels and bread units. This meter was developed in cooperation with two market leading international companies for worldwide use in all target groups.


About Emperra E-Health Technologies
Emperra GmbH E-Health Technologies is a research and development-driven medical technology start-up company from Potsdam providing innovative concepts and solutions in the fields of e-health technologies and telediabetology. Emperra combines progressive software with pioneering hardware and integrates this into a medical, scientific concept to provide telemedical product systems for doctors, patients, caregivers and relatives.


Contact

EMPERRA® GmbH E-Health Technologies
Dr. Janko Schildt, CMO/CSO
Friedrich-Ebert-Straße 33
D-14469 Potsdam, Germany
+49 331-979 34 80 -22
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.emperra.com